

**Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss**

Ker K\*, Prieto-Merino D, Roberts I

Clinical Trials Unit

London School of Hygiene & Tropical Medicine

Keppel Street

London WC1E 7HT

UK

\*corresponding author

Email [katharine.ker@lshtm.ac.uk](mailto:katharine.ker@lshtm.ac.uk)

Tel +44 (0) 20 7958 8135

Fax +44 (0)20 7299 4663

Source of funding: LSHTM Clinical Trials Unit

Manuscript category: Meta-analysis

## **Abstract**

### ***Background***

Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of the reduction in blood loss and how it relates to the dose of TXA is unclear.

### ***Methods***

A systematic review of randomised trials was performed. Data were extracted on blood loss from trials comparing intravenous TXA with no TXA or placebo in surgical patients. A Bayesian linear regression was used to describe the relationship between the reduction in blood loss with TXA and the extent of bleeding as measured by the mean blood loss in the control group. A meta-analysis of the log-transformed data was conducted to quantify the effect of TXA on blood loss, stratified by type of surgery, timing of TXA administration and trial quality. Meta-regression was used to explore the effect of TXA dose.

### ***Results***

Data from 104 trials were examined. Although the absolute reduction in blood loss with TXA increased as surgical bleeding increased, the percentage reduction was similar. TXA reduced blood loss by 34% (pooled ratio=0.66, 95% CI 0.65 to 0.67;  $P < 0.001$ ). The percentage reductions in blood loss with TXA differed by type of surgery, timing of TXA administration and trial quality but the differences were small. The effect of TXA on blood loss did not vary over the range of doses assessed (5.5 to 300 mg/kg).

### ***Conclusions***

TXA reduces blood loss in surgical patients by about a third. A total dose of 1g appears to be sufficient for most adults. There is no evidence to support the use of high doses.

## **Introduction**

Tranexamic acid (TXA) reduces the probability of receiving a blood transfusion in surgery. A systematic review of randomised controlled trials showed that TXA reduces the probability of blood transfusion by 38% (pooled risk ratio=0.62, 95% CI 0.58 to 0.65;  $P<0.001$ )<sup>[1]</sup>. However, the extent to which TXA reduces surgical bleeding and its relationship with the dose of TXA and type of surgery remains uncertain. Because the decision to transfuse depends on factors other than blood loss, the effect on blood transfusion may not be an accurate indicator of the effect of TXA on surgical bleeding.

Clinical trials of TXA in surgery usually report the mean blood loss in each group. Previous systematic reviews have combined these data to obtain the average difference in mean blood loss between the TXA and control groups. However, the usefulness of such a measure is questionable. It would be surprising if TXA reduced blood loss by the same volume in surgical procedures that involve different amounts of bleeding. On the other hand, it may be reasonable to expect a similar percentage reduction in blood loss with TXA.

The objective of this study is to examine whether the effect of TXA on blood loss varies with the extent of surgical bleeding. The magnitude of the percentage reduction in blood loss with TXA is estimated and how the effect varies by type of surgery, timing of TXA administration, trial quality, and dose is assessed.

## **Methods**

A systematic review of randomised controlled trials of TXA in surgical patients was conducted. The methods used to identify trials for the review are described in detail elsewhere<sup>[1]</sup>. In brief, a comprehensive search was undertaken for all randomised controlled trials comparing intravenous TXA with placebo or no intervention in elective or emergency surgery. Two authors screened the

search output and the full texts of all eligible trials were obtained. Information was extracted on patient characteristics, type of surgery, dose and timing of TXA administration and average blood loss (mean and standard deviation). The risk of bias associated with sequence generation, allocation concealment, blinding, and the completeness of outcome data was assessed for each trial.

### ***Data analysis***

To explore the relationship between the reduction blood loss with TXA and the extent of bleeding, for each trial the mean blood loss in the TXA group was plotted against the mean blood loss in the control group. This relationship was examined using a linear regression estimated using a Bayesian model as proposed by Thompson *et al*<sup>[2]</sup> to account for random sampling error in the estimates of the regression variables (i.e. in the sample means from each trial). Statistical details of the model are given in Supplementary File 1.

To quantify the effect of TXA on the percentage reduction in blood loss, a meta-analysis using both fixed and random effects models was conducted. For the purpose of the meta-analysis, blood loss data were log transformed and the analysis conducted using the transformed values. The formulae used for the transformations are given in Supplementary File 1. A meta-analysis (using arithmetic means) of the differences in means using the transformed blood loss data corresponds to a meta-analysis (using geometric means) of the ratio of means in the original scale. The pooled estimates were back-transformed to give the blood loss ratios and 95% confidence intervals on the original scale. Statistical heterogeneity was examined by visual inspection of forest plots, the  $I^2$  statistic and the  $\chi^2$  test.

Subgroup analyses were undertaken to assess the effect of TXA by the type of surgery, timing of TXA administration (pre-incision, post-incision), allocation concealment (adequate, unclear, inadequate) and type of comparator (placebo or no intervention). Heterogeneity between subgroups was assessed using the  $\chi^2$  test (fixed effect analysis only). Finally, a random effects meta-regression was carried out to investigate the association between the effect of TXA on blood loss and the total dose

of TXA (mg/kg) as a continuous variable. If a fixed dose was used in the trials (e.g. 1000mg) it was converted to mg/kg by dividing by 70kg. A funnel plot was inspected for the presence of small study effects. We used STATA (version 12)<sup>[3]</sup> statistical software for all analyses.

## **Results**

Figure 1 shows the trial selection process. One hundred and twenty-nine randomised controlled trials were identified. The characteristics of the included trials are summarised in Supplementary File 2. Nine reports described multi-arm trials involving a total of 23 eligible pair-wise comparisons; each of these was included in the analysis as separate trials. One hundred and four randomised comparisons described in 90 articles, reported data on blood loss in a format suitable for this analysis<sup>[4-93]</sup>. These trials involved a total of 8030 patients, 4224 received TXA and 3806 received a placebo or no intervention.

The trials involved cardiac (n=54), orthopaedic (n=33), obstetric & gynaecological (n=7), head & neck (n=7), breast cancer (n=1), hepatic (n=1) and urological (n=1) surgery. Eighty trials gave TXA prior to surgical incision and 24 trials gave TXA after incision. Thirty-three trials were assessed as being adequately concealed (low risk of bias), five trials as inadequately concealed (high risk of bias). The remaining 66 trials presented insufficient information on allocation concealment to allow judgement and were rated as unclear. Seventy-five trials were placebo-controlled, whereas a no intervention group was used as the control in the remaining 29 trials.

### ***Effect of TXA on blood loss***

Figure 2 shows the relationship between mean blood loss in the TXA group and mean blood loss in the control group. The mean blood loss in the TXA group increased as the mean blood loss in the control group increased, but to a lesser extent. The intercept of the regression line (dotted line) estimated by the Bayesian model was 4 ml (95% credibility interval -8 ml to 18 ml), a negligible value in the context of the observed blood loss estimates. The Bayesian model corresponded closely with

the regression line predicted assuming a constant percentage reduction in blood loss (dashed line) and an intercept of zero.

Figure 3 shows the summary results of a fixed effect meta-analysis of the percentage reduction in blood loss with TXA. A forest plot showing the estimates from each trial is shown in Supplementary File 3. The back-transformed pooled ratio of blood loss with TXA was 0.66 (95% CI 0.65 to 0.67;  $P < 0.001$ ) indicating that TXA reduced blood loss by 34%. There was substantial statistical heterogeneity between trials ( $I^2 = 83\%$ ). There was heterogeneity in the magnitude of effect by type of surgery although the extent of the variation was small. All of the subgroup estimates were consistent with a reduction in blood loss, and all but one was statistically significant at the 5% level. TXA had a greater effect on blood loss when given after incision, although the difference between the pre and post-incision estimates was small. There was heterogeneity in the magnitude of effect by adequacy of allocation concealment. When the analysis restricted to the 33 adequately concealed trials, TXA reduced blood loss by 30% (0.70, 95% CI 0.68 to 0.72;  $P < 0.001$ ). There was no evidence for heterogeneity in the estimated effects of TXA when compared to a placebo or a no intervention control group. The results from random effects meta-analyses were similar to the fixed effect analyses and are shown in Supplementary File 4.

A fixed dose was converted to the equivalent mg/kg dose in 21 trials. The total dose of TXA used in the trials ranged from 5.5mg/kg to 300mg/kg. The median dose was 22mg/kg with the majority of trials (70%) using a total dose of 30mg/kg or less. Results from the meta-regression suggested that the effect of TXA on blood loss did not vary over the dose range assessed (coefficient=0.889, 95% CI 0.787 to 1.004;  $P = 0.059$ ).

There was no clear asymmetry in the funnel plot (Figure 4).

## **Discussion**

Tranexamic acid reduces surgical blood loss by about a third. Although the magnitude of the reduction differs by type of surgery and timing of TXA administration, the differences are small and

are unlikely to be clinically important. A total dose of 1g is likely to be sufficient for most adults and there is no evidence to support the use of high doses.

The validity of these results depends on the quality of the included trials and many were of low quality. Less than a third of trials were judged to be at low risk of bias on the basis of allocation concealment. Nevertheless, even when the analysis was restricted to adequately concealed trials, the effect of TXA on blood loss remained large and highly statistically significant.

Statistical heterogeneity between trials was substantial and was not explained by type of surgery, trial quality, the timing of TXA administration or dose. Differences in the methods used to estimate blood loss, the duration over which blood loss was measured, and other aspects of trial quality may explain some of the heterogeneity.

The subgroup analyses showed that the effect of TXA on blood loss varied by type of surgery, trial quality and timing of TXA. However, the extent of the variation was small and the clinical importance of such small variations is questionable.

There was no obvious asymmetry in the funnel plot, but reporting bias remains a concern particularly as about one fifth of trials were not included in the analysis due to unsuitable data or inadequate reporting. If many of these or other unpublished trials, showed little or no effect of TXA on blood loss, the analysis would have overestimated the treatment effect. Although, in consideration of the magnitude and precision of the effect, it is unlikely that any such bias would account for all of the observed effect.

The reduction in bleeding with TXA is almost identical to the reduction in the risk of receiving a blood transfusion with TXA suggesting that in surgery, transfusion may be closely titrated to blood loss. This might not be the case in trauma patients. The CRASH-2 trial found that early administration of TXA reduced the risk of death due to bleeding by about one third but there was no clear reduction in the risk of receiving a blood transfusion<sup>[94, 95]</sup>.

Although there is reliable evidence that TXA reduces bleeding and blood transfusion in surgery, its effect on other important outcomes including death and thromboembolic events remains uncertain<sup>[1]</sup>. There is no evidence that it increases the risk of thromboembolic events but it is a theoretical concern that may deter some surgeons from using TXA. These uncertainties need to be resolved before TXA can be recommended for routine use in surgery.

The apparent lack of a dose-response relationship across the range of doses examined (5.5 to 300 mg/kg) has important implications for the use of TXA in surgery. TXA crosses the blood brain barrier and there is some evidence from observational studies of patients undergoing cardiac surgery that high-dose TXA ( $\geq 100$  mg/kg) may cause seizures<sup>[96, 97]</sup>. Our results imply that the clinical benefit of TXA on bleeding can be achieved at doses much lower than those associated with such adverse effects. Indeed, a total dose of about 14 mg/kg (or about 1g in adults) appears to be sufficient for most patients.

### **Acknowledgements**

### **Conflicts of interest**

None known

### **References**

1. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. *BMJ* 2012;344:e3054.
2. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. *Statistics in medicine* 1997;16(23):2741-2758.
3. StatCorp, *Stata Statistical Software: Release 11*. College Station, TX: StataCorp LP. 2009.
4. Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. *Transfusion* 2008;48(3):519-525.

5. Armellin G, Casella S, Guzzinati S, Pasini L, Marcassa A, Giron G. Tranexamic acid in aortic valve replacement. *Journal of cardiothoracic and vascular anesthesia* 2001;15(3):331-335.
6. Auvinen O, Baer GA, Nordback I, Saaristo J. Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland. *Klinische Wochenschrift* 1987;65(6):253-255.
7. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. *The Journal of bone and joint surgery. British volume* 1996;78(3):434-440.
8. Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. *Acta orthopaedica Scandinavica* 2001;72(5):442-448.
9. Blauhut B, Harringer W, Bettelheim P, Doran JE, Späth P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1994;108(6):1083-1091.
10. Bulutcu FS, Ozbek U, Polat B, Yalçın Y, Karaci AR, Bayindir O. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? *Paediatric anaesthesia* 2005;15(1):41-46.
11. Caglar GS, Tasci Y, Kayikcioglu F, Haberal A. Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. *European journal of obstetrics, gynecology, and reproductive biology* 2008;137(2):227-231.
12. Casati V, Della Valle P, Benussi S, Franco A, Gerli C, Baili P, *et al.* Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques. *The Journal of thoracic and cardiovascular surgery* 2004;128(1):83-91.
13. Chauhan S, Bisoi A, Kumar N, Mittal D, Kale S, Kiran U, *et al.* Dose comparison of tranexamic acid in pediatric cardiac surgery. *Asian cardiovascular & thoracic annals* 2004;12(2):121-124.

14. Chauhan S, Bisoi A, Modi R, Gharde P, Rajesh MR. Tranexamic acid in paediatric cardiac surgery. *The Indian journal of medical research* 2003;118:86-89.
15. Chauhan S, Das SN, Bisoi A, Kale S, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. *Journal of cardiothoracic and vascular anesthesia* 2004;18(2):141-143.
16. Chen CC, Wang CC, Wang CP, Lin TH, Lin WD, Liu SA. Prospective, randomized, controlled trial of tranexamic acid in patients who undergo head and neck procedures. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery* 2008;138(6):762-767.
17. Choi WS, Irwin MG, Samman N. The effect of tranexamic acid on blood loss during orthognathic surgery: a randomized controlled trial. *Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons* 2009;67(1):125-133.
18. Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. *Acta chirurgica Belgica* 2007;107(4):397-401.
19. Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. *The American surgeon* 1995;61(7):566-568.
20. Corbeau JJ, Monrigal JP, Jacob JP, Cottineau C, Moreau X, Bukowski JG, *et al.* [Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery]. [French]. *Annales Francaises d Anesthesie et de Reanimation* 1995;14(2):154-161.
21. Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, *et al.* Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. *BMJ* 2011;343:d5701.
22. Dadure C, Sauter M, Bringuier S, Bigorre M, Raux O, Rochette A, *et al.* Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. *Anesthesiology* 2011;114(4):856-861.

23. Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. *British journal of anaesthesia* 2005;94(3):271-278.
24. Durán de la Fuente P, García-Fernández J, Pérez-López C, Carceller F, Gilsanz Rodríguez F. [Usefulness of tranexamic acid in cranial remodeling surgery]. *Revista española de anestesiología y reanimación* 2003;50(8):388-394.
25. Ekbäck G, Axelsson K, Rytberg L, Edlund B, Kjellberg J, Weckström J, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. *Anesthesia and analgesia* 2000;91(5):1124-1130.
26. Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. *Spine* 2008;33(24):2577-2580.
27. Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. *European journal of obstetrics, gynecology, and reproductive biology* 2004;112(2):154-157.
28. Garneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. *The Journal of arthroplasty* 2004;19(4):488-492.
29. Gobbur VR, Reddy SV, Usha J, Bijapur. Efficacy of tranexamic acid in reducing blood loss during lower segment caesarean section. *54th All India Congress of Obstetrics and Gynaecology; 2011 January 5-9; Hyderabad, Andhra Pradesh, India. 2011:92. 2011.*
30. Gohel M, Patel P, Gupta A, Desai P. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. *Journal of Obstetrics and Gynaecology of India* 2007;57(3):228-230.

31. Goobie SM, Meier PM, Pereira LM, McGowan FX, Prescilla RP, Scharp LA, *et al.* Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. *Anesthesiology* 2011;114(4):862-871.
32. Greiff G, Stenseth R, Wahba A, Videm V, Lydersen S, Irgens W, *et al.* Tranexamic Acid Reduces Blood Transfusions in Elderly Patients Undergoing Combined Aortic Valve and Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial. *J Cardiothorac Vasc Anesth* 2012;26(2):232-238.
33. Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of Intravenous Tranexamic Acid in Reducing Blood Loss after Elective Cesarean Section: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. *Am J Perinatol* 2010.
34. Hiippala S, Strid L, Wennerstrand M, Arvela V, Mäntylä S, Ylinen J, *et al.* Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. *British journal of anaesthesia* 1995;74(5):534-537.
35. Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemelä HM, Mäntylä SK, *et al.* Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. *Anesthesia and analgesia* 1997;84(4):839-844.
36. Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, *et al.* Prophylactic tranexamic acid decreases bleeding after cardiac operations. *The Journal of thoracic and cardiovascular surgery* 1990;99(1):70-74.
37. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. *Circulation* 1991;84(5):2063-2070.
38. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. *Anesthesiology* 1995;82(2):383-392.
39. Husted H, Blønd L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. *Acta orthopaedica Scandinavica* 2003;74(6):665-669.

40. Isetta C, Guinness TK, Samat C, Paolini G, Lugrin D, Sanchez B, *et al.* Antifibrinolytic treatment and homologous transfusion in cardiac surgery. *European Heart Surgery* 1993;14(Suppl):424.
41. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. *British journal of anaesthesia* 1999;83(4):596-601.
42. Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, *et al.* Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. *Critical care (London, England)* 2007;11(6):R117.
43. Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. *Acta orthopaedica* 2005;76(3):314-319.
44. Kakar PN, Gupta N, Govil P, Shah V. Efficacy and safety of Tranexamic Acid in control of bleeding following TKR: a randomized control trial. *Indian Journal of Anaesthesia* 2009;53(6):667-671.
45. Karski J, Djaiani G, Carroll J, Iwanochko M, Seneviratne P, Liu P, *et al.* Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial. *The Journal of thoracic and cardiovascular surgery* 2005;130(2):309-314.
46. Karski JM, Teasdale SJ, Norman P, Carroll J, VanKessel K, Wong P, *et al.* Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. *The Journal of thoracic and cardiovascular surgery* 1995;110(3):835-842.
47. Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y. Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations. *The Journal of thoracic and cardiovascular surgery* 1997;113(4):802-804.

48. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. *The Annals of thoracic surgery* 1996;61(4):1131-1135.
49. Kazemi SM, Mosaffa F, Eajazi A, Kaffashi M, Besheli LD, Bigdeli MR, *et al.* The effect of tranexamic acid on reducing blood loss in cementless total hip arthroplasty under epidural anesthesia. *Orthopedics* 2010;33(1):17.
50. Kojima T, Gando S, Morimoto Y, Mashio H, Goda Y, Kawahigashi H, *et al.* Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery. *Thrombosis research* 2001;104(5):301-307.
51. Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenperä M. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. *Acta anaesthesiologica Scandinavica* 2005;49(9):1272-1279.
52. Kuitunen AH, Suojaranta-Ylinen RT, Kukkonen SI, Niemi TT. Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery. *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis* 2006;17(8):639-645.
53. Leelahanon S, Singhatanadgige S, Luengtaviboon K, Cheanvechai C, Benjacholamas V, Namchaisiri J, *et al.* Can Tranexamic Acid Improve Post Cardiopulmonary Bypass Hemostasis? A Double-Blind Prospective Randomized Placebo-Controlled Study. *Thai Journal of Surgery* 2002;23(4):138.
54. Lemay E, Guay J, Côté C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. *Canadian journal of anaesthesia = Journal canadien d'anesthésie* 2004;51(1):31-37.
55. Lin PC, Hsu CH, Chen WS, Wang JW. Does tranexamic acid save blood in minimally invasive total knee arthroplasty? *Clin Orthop Relat Res* 2011;469(7):1995-2002.

56. MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT. Tranexamic Acid to Reduce Blood Loss After Bilateral Total Knee Arthroplasty A Prospective, Randomized Double Blind Study. *J Arthroplasty* 2011;26(1):24-28.
57. Maddali MM, Rajakumar MC. Tranexamic acid and primary coronary artery bypass surgery: a prospective study. *Asian cardiovascular & thoracic annals* 2007;15(4):313-319.
58. Mehr-Aein A, Davoodi S, Madani-Civi M. Effects of tranexamic acid and autotransfusion in coronary artery bypass. *Asian cardiovascular & thoracic annals* 2007;15(1):49-53.
59. Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, Di Giovanni C, *et al.* Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. *The Journal of cardiovascular surgery* 1996;37(4):401-407.
60. Misfeld M, Dubbert S, Eleftheriadis S, Siemens HJ, Wagner T, Sievers HH. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations. *The Annals of thoracic surgery* 1998;66(3):792-799.
61. Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. *The Journal of bone and joint surgery. British volume* 2007;89(3):306-309.
62. Moret F, Flo A, Escudero A, Masso E, Munoz S, Ruyra X, *et al.* Tranexamic acid reduces postoperative bleeding but not allogeneic transfusion requirements in valve replacement cardiac surgery. *Transfusion Alternatives in Transfusion Medicine* 2006;8(1 (Suppl)):93.
63. Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. *International Journal of Gynaecology and Obstetrics* 2011;115(3):224-226.
64. Murphy GJ, Mango E, Lucchetti V, Battaglia F, Catapano D, Rogers CA, *et al.* A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials

evaluating tranexamic acid in off-pump coronary artery bypass grafting. *The Journal of thoracic and cardiovascular surgery* 2006;132(3):475-480, 480.e471-478.

65. Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. *Anesthesia and analgesia* 2001;93(1):82-87.

66. Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. *Acta orthopaedica* 2005;76(6):829-832.

67. Oertli D, Laffer U, Haberthuer F, Kreuter U, Harder F. Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. *The British journal of surgery* 1994;81(6):856-859.

68. Orpen NM, Little C, Walker G, Crawford EJ. Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. *The Knee* 2006;13(2):106-110.

69. Ozal E, Kuralay E, Bingöl H, Cingöz F, Ceylan S, Tatar H. Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis? *The Journal of thoracic and cardiovascular surgery* 2002;123(3):539-543.

70. Penta de Peppo A, Pierri MD, Scafuri A, De Paulis R, Colantuono G, Caprara E, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. *Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital* 1995;22(3):231-236.

71. Pfizer. Prospective randomised phase IV open label comparative study of tranexamic acid plus standard care versus standard care for the reduction of blood loss in subjects undergoing surgery for long bone fracture. *PhRMA Web Synopsis. Protocol B1461005 - 05 May 2011 - Final* 2011.

72. Pinosky ML, Kennedy DJ, Fishman RL, Reeves ST, Alpert CC, Ecklund J, *et al.* Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo. *Journal of cardiac surgery* 1997;12(5):330-338.
73. Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. *Anesthesia and analgesia* 2003;96(4):923-928, table of contents.
74. Sadeghi M, Mehr-Aein A. Does a single bolus dose of tranexamic acid reduce blood loss and transfusion requirements during hip fracture surgery? A prospective randomized double blind study in 67 patients. *Acta Medica Iranica* 2007;45(6):437-442.
75. Sekhavat L, Tabatabaai A, Dalili M, Farajkhoda T, Tafti AD. Efficacy of tranexamic acid in reducing blood loss after cesarean section. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians* 2009;22(1):72-75.
76. Senghore N, Harris M. The effect of tranexamic acid (cyclokapron) on blood loss after third molar extraction under a day case general anaesthetic. *British dental journal* 1999;186(12):634-636.
77. Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. *Anesthesiology* 2005;102(4):727-732.
78. Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. *Anesthesia and analgesia* 1996;83(1):18-26.
79. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijssman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. *The Annals of thoracic surgery* 1995;59(2):438-442.

80. Taghaddomi RJ, Mashhadinezhad H, Attar ARS, Peivandi A. The effect of intravenous tranexamic acid on blood loss in lumbar hernial disc resection under inhalation and total intravenous anesthesia. *Iranian Red Crescent Medical Journal* 2009;11(3):265-270.
81. Taghaddomi RJ, Mirzaee A, Attar AS, Shirdel A. Tranexamic Acid Reduces Blood Loss in Off-Pump Coronary Artery Bypass Surgery. *Journal of Cardiothoracic and Vascular Anesthesia* 2009;23(3):312-315.
82. Tsutsumimoto T, Shimogata M, Ohta H, Yui M, Yoda I, Misawa H. Tranexamic Acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. *Spine (Phila Pa 1976)* 2011;36(23):1913-1918.
83. Uozaki Y, Watanabe G, Kotou K, Ueyama K, Doi Y, Misaki T. Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass. *The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery* 2001;49(5):273-278.
84. Vanek T, Jares M, Fajt R, Straka Z, Maly M. [Antifibrinolytic agents in off-pump cardiac surgery: Analysis of blood loss, safety and cost-effectiveness]. *Anesteziologie a Intenzivni Medicina* 2006;17(1):6-13.
85. Veien M, Sørensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. *Acta anaesthesiologica Scandinavica* 2002;46(10):1206-1211.
86. Wang G, Xie G, Jiang T, Wang Y, Wang W, Ji H, *et al.* Tranexamic Acid Reduces Blood Loss After Off-Pump Coronary Surgery: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. *Anesth Analg* 2011.
87. Wong J, El Beheiry H, Rampersaud YR, Lewis S, Ahn H, De Silva Y, *et al.* Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery. *Anesthesia and analgesia* 2008;107(5):1479-1486.

88. Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. *The Journal of bone and joint surgery. American volume* 2005;87(4):766-770.
89. Yassen K, Bellamy MC, Sadek SA, Webster NR. Tranexamic acid reduces blood loss during orthotopic liver transplantation. *CLIN. TRANSPLANT.* 1993;7(5):453-458.
90. Zabeeda D, Medalion B, Sverdlov M, Ezra S, Schachner A, Ezri T, *et al.* Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization. *The Annals of thoracic surgery* 2002;74(3):733-738.
91. Zhang F, Gao Z, Yu J. [Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty]. [Chinese]. *Chung-Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih/Chinese Journal of Reparative & Reconstructive Surgery* 2007;21(12):1302-1304.
92. Zohar E, Ellis M, Ifrach N, Stern A, Sapir O, Fredman B. The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement. *Anesthesia and analgesia* 2004;99(6):1679-1683, table of contents.
93. Zonis Z, Seear M, Reichert C, Sett S, Allen C. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. *The Journal of thoracic and cardiovascular surgery* 1996;111(5):982-987.
94. CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010;376(9734):23-32.
95. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, *et al.* The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. *Lancet* 2011;377(9771):1096-1101, 1101 e1091-1092.
96. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. *Ann Thorac Surg* 2012;93(1):148-154.

97. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. *Anesth Analg* 2010;110(2):350-353.